source
- Three series-C funded biotechs expand hiring, including Triveni Bio’s $65 M raiseThree biotechnology companies that announced series C financing this year are actively hiring, signaling plans to scale operations. One of the firms secured a $140 million round and maintains offic…
- FDA rejects Summit Therapeutics' PD-1/VEGF bispecific ivonescimab after Phase 3 failureThe U.S. Food and Drug Administration declined to grant approval for ivonescimab, a bispecific antibody that targets PD‑1 and VEGF and was being developed by Summit Therapeutics in collaboration wi…